Article
Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
The pharmacogenomics journal - 1 Aug 2014
Wiese M D, Alotaibi N, O'Doherty C, Sorich M J, Suppiah V, Cleland L G, Proudman S M
Abstract excerpt
Sulphasalazine (SSA) is a disease modifying anti-rheumatic drug (DMARD) that is commonly used to treat rheumatoid arthritis (RA). Plasma levels of SSA and its metabolite sulphapyridine are influenced by common polymorphisms in genes that encode N-acetyl transferase 2 (NAT2) and ATP-binding cassette protein G2 (ABCG2). Study participants had early RA that was treated with a combination DMARD regimen that included...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
